HIV Treatment as Prevention: Issues in Economic Evaluation

English version České info

Meyer-Rath and Over assert in another article in the July 2012 PLoS Medicine Collection, “Investigating the Impact of Treatment on New HIV Infections”, that economic evaluations of antiretroviral therapy (ART) in currently existing programs and in HIV treatment as prevention (TasP) programs should use cost functions that capture cost dependence on a number of factors, such as scale and scope of delivery, health states, ART regimens, health workers' experience, patients' time on treatment, and the distribution of delivery across public and private sectors. We argue that for particular evaluation purposes (e.g., to establish the social value of TasP) and from particular perspectives (e.g., national health policy makers) less detailed cost functions may be sufficient. We then extend the discussion of economic evaluation of TasP, describing why ART outcomes and costs assessed in currently existing programs are unlikely to be generalizable to TasP programs for several fundamental reasons. First, to achieve frequent, widespread HIV testing and high uptake of ART immediately following an HIV diagnosis, TasP programs will require components that are not present in current ART programs and whose costs are not included in current estimates. Second, the early initiation of ART under TasP will change not only patients' disease courses and treatment experiences—which can affect behaviors that determine clinical treatment success, such as ART adherence and retention—but also quality of life and economic outcomes for HIV-infected individuals. Third, the preventive effects of TasP are likely to alter the composition of the HIV-infected population over time, changing its biological and behavioral characteristics and leading to different costs and outcomes for ART.

Vyšlo v časopise: HIV Treatment as Prevention: Issues in Economic Evaluation. PLoS Med 9(7): e32767. doi:10.1371/journal.pmed.1001263
Kategorie: Review
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001263

Souhrn

Zdroje

1. CohenMSChenYQMcCauleyMGambleTHosseinipourMC 2011 Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365 493 505

2. GranichRGuptaSSutharABSmythCHoosD 2011 Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 9 446 469

3. BoilyMCMâsseBAlsallaqRPadianNSEatonJW 2012 HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med 9 e1001250 doi:10.1371/journal.pmed.1001250

4. HontelezJAde VlasSJTanserFBakkerRBärnighausenT 2011 The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS ONE 6 e21919 doi:10.1371/journal.pone.0021919

5. LongEFBrandeauMLOwensDK 2010 The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 153 778 789

6. VijayaraghavanAEfrusyMBMazonsonPDEbrahimOSanneIM 2007 Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr 46 91 100

7. EatonJWJohnsonLFSalomonJABärnighausenTBendavidE 2012 HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 9 e1001245 doi:10.1371/journal.pmed.1001245

8. Meyer-RathGOverM 2012 HIV treatment as prevention: modelling the cost of antiretroviral treatment—state of the art and future directions. PLoS Med 9 e1001247 doi:10.1371/journal.pmed.1001247

9. BärnighausenTKyleMSalomonJAWaningB 2011 Assessing the population health impact of market interventions to improve access to antiretroviral treatment. Health Policy Plan E-pub ahead of print. doi:10.1093/heapol/czr058

10. GuinnessLKumaranayakeLHansonK 2007 A cost function for HIV prevention services: is there a ‘u’ - shape? Cost Eff Resour Alloc 5 13

11. GuinnessLKumaranayakeLRajaramanBSankaranarayananGVannelaG 2005 Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India. Bull World Health Organ 83 747 755

12. MarseilleEDandonaLMarshallNGaistPBautista-ArredondoS 2007 HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res 7 108

13. GranichRMGilksCFDyeCDe CockKMWilliamsBG 2009 Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373 48 57

14. HallettTBGregsonSDubeSMapfekaESMugurungiO 2011 Estimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe. Sex Transm Infect 87 621 628

15. NashDWuYElulBHoosDEl SadrW 2011 Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries. AIDS 25 1523 1533

16. LahuertaMHoffmanSElulBWuYGorrell KulkarniS 2012 Change over time in CD4+ count and disease stage at entry into HIV care—findings from 9 sub-Saharan African countries [abstract]. 19th Conference on Retroviruses and Opportunistic Infections; 5–8 March 2012; Seattle, Washington, US

17. South African Department of Health 2010 HIV counselling and testing (HCT) policy guidelines Pretoria South African Department of Health

18. BärnighausenTTanserFDabisFNewellM 2012 Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence. Curr Opin HIV AIDS 11 942 951

19. BärnighausenTChaiyachatiKChimbindiNPeoplesAHabererJ 2011 Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis 11 942 951

20. HallettTBBaetenJMHeffronRBarnabasRde BruynG 2011 Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 8 e1001123 doi:10.1371/journal.pmed.1001123

21. SterneJMayMCostagliolaDEggerMHoggR 2006 Early HAART associated with improved outcomes & fewer toxicities [abstract]. 13th Conference on Retroviruses and Opportunistic Infections; 5–8 February 2006; Denver, Colorado, US

22. LichtensteinKArmonCBuchaczKMoormanAWoodK 2006 Early, uninterrupted ART is associated with improved outcomes and fewer toxicities in the HIV outpatient study (HOPS) [abstract]. 13th Conference on Retroviruses and Opportunistic Infections; 5–8 February 2006; Denver, Colorado, US

23. ArmonCLichtensteinK 2011 The associations among coping, nadir CD4+ T-cell count, and non-HIV-related variables with health-related quality of life among an ambulatory HIV-positive patient population. Qual Life Res E-pub ahead of print. doi:10.1007/s11136-011-0017-2

24. Panel on Antiretroviral Guidelines for Adults and Adolescents 2012 Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington (District of Columbia): US Department of Health and Human Services

25. ThirumurthyHGraff ZivinJGoldsteinMP 2005 The economic impact of AIDS treatment: labor supply in western Kenya. J Hum Res 43 511 552

26. RosenSKetlhapileMSanneIDesilvaMB 2008 Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. AIDS 22 Suppl 1 S131 S139

27. LarsonBAFoxMPRosenSBiiMSigeiC 2008 Early effects of antiretroviral therapy on work performance: preliminary results from a cohort study of Kenyan agricultural workers. AIDS 22 421 425

28. BorJTanserFNewellMLBärnighausenT 2012 Nearly full employment recovery among HIV patients on antiretroviral therapy: evidence from a large population cohort. Health Aff (Millwood) In press

29. HontelezJALurieMNNewellMLBakkerRTanserF 2011 Ageing with HIV in South Africa. AIDS 25 1665 1667

30. HontelezJAde VlasSJBaltussenRBakkerRTanserF 2012 The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa. AIDS In press